1339084-93-3

Upstream product

• 696-59-3 cis,trans-2,5-dimethoxytetrahydrofuran 
• 1341216-35-0 3-fluoro-4-hydroxybenzenaminium chloride 
• 403-19-0 2-fluoro-4-nitrophenol 
• 109-97-7 pyrrole 
• 2105-94-4 4-bromo-2-fluorophenol 

Downstream Products

• 1594781-87-9 [1-(3-fluoro-4-hydroxyphenyl)-1H-pyrrol-3-yl](4-methoxyphenyl)methanone 
• 1594782-21-4 1-(4-benzoyl-1-(3-fluoro-4-hydroxyphenyl)-1H-pyrrol-2-yl)-2,2-difluoroethanone 
• 1594782-20-3 1-[4-benzoyl-1-(3-fluoro-4-hydroxyphenyl)-1H-pyrrol-2-yl]-2,2,2-trifluoroethanone 
• 1594781-95-9 [1,1'-biphenyl]-4-yl(1-(3-fluoro-4-hydroxyphenyl)-1H-pyrrol-3-yl)methanone 
• 1594781-94-8 [1-(3-fluoro-4-hydroxyphenyl)-1H-pyrrol-3-yl](4-bromo-2-fluorophenyl)methanone 
• 1594781-89-1 [1-(3-fluoro-4-hydroxyphenyl)-1H-pyrrol-3-yl](3-methoxyphenyl)methanone 
• 1594781-85-7 [1-(3-fluoro-4-hydroxyphenyl)-1H-pyrrol-3-yl]phenylmethanone 
• 1594782-23-6 2,2-difluoro-1-(1-(3-fluoro-4-hydroxyphenyl)-1H-pyrrol-2-yl)ethanone 
• 1594782-22-5 2,2,2-trifluoro-1-(1-(3-fluoro-4-hydroxyphenyl)-1H-pyrrol-2-yl)ethanone 

Relevant academic research and scientific papers

Clauson-kaas-type synthesis of pyrrolyl-phenols, from the hydrochlorides of aminophenols, in the presence of nicotinamide

A facile Clauson-Kaas-type pyrrolyl-phenol synthesis has been achieved in the presence of nicotinamide, which is inexpensive and nontoxic. The starting material is aminophenol hydrochloride. This is advantageous in certain cases because it is the only isolatable form of the corresponding aminophenol.

MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO

The present invention relates to compounds of Formula I and pharmaceutically acceptable salts, solvates, and hydrates thereof, that are useful as single pharmaceutical agents or in combination with one or more additional pharmaceutical agents, such as, a DPP-IV inhibitor, a biguanide, an alpha-glucosidase inhibitor, an insulin analogue, a sulfonylurea, an SGLT2 inhibitor, a meglitinide, a thiazolidinedione, or an anti-diabetic peptide analogue, in the treatment of, for example, a disorder selected from: a GPR119-receptor-related disorder; a condition ameliorated by increasing a blood incretin level; a condition characterized by low bone mass; a neurological disorder; a metabolic-related disorder; type 2 diabetes; obesity; and complications related thereto.